Document is current
Any future updates will be listed below
-
Authors
Zeng, Jingkun
Cheng, Zhiyuan https://orcid.org/0009-0000-3474-2422
Chen, Huadong
Wang, Zhaojun
Thompson, Jared https://orcid.org/0009-0006-8557-9702
Crosby, Kadin T. https://orcid.org/0009-0001-0201-5340
Han, Hesong https://orcid.org/0000-0001-5545-5238
Singhal, Arushi
Ngo, Wayne https://orcid.org/0000-0002-5755-2303
Xia, Chenglong https://orcid.org/0000-0002-5895-6342
Rosas-Rivera, Daniel
Zhang, Zeyuan
Kang, Min Hyung
Mao, Ying
Diolaiti, Morgan E. https://orcid.org/0000-0001-5900-3060
Lee, Giselle C. https://orcid.org/0000-0002-1794-3094
Diffley, John F. X. https://orcid.org/0000-0001-5184-7680
Song, Yixuan
Qiu, Longhui
Krah, Nathan M. https://orcid.org/0009-0003-8297-7359
Murthy, Niren https://orcid.org/0000-0002-7815-7337
Jackson, Ryan N. https://orcid.org/0000-0001-7403-3794
Liu, Yang https://orcid.org/0000-0002-3889-9707
Ashworth, Alan https://orcid.org/0000-0003-1446-7878
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
- License Information
-
More Information
Article History
Received: 4 November 2025
Accepted: 29 May 2026
First Online: 8 June 2026
Ethics
Competing interests: A patent application has been filed for CRISPR technologies on which J.Z., J.A.D., R.N.J., K.T.C. and Y.L. are inventors. J.A.D. is a co-founder of Aurora, Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Scribe Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member at BEVC Management, Caribou Biosciences, Scribe Therapeutics, Isomorphic Labs, The Column Group and Inari; and also an adviser for Aditum Bio. J.A.D. is chief science adviser to Sixth Street and a director at Johnson & Johnson, Altos and Tempus. A.A. is a co-founder of Azkarra Therapeutics, Kytarro, Ovibio Corporation, Tango Therapeutics and Tiller Tx; is a member of the board of Cambridge Science Corporation, Cytomx and Ovibio, a member of the scientific advisory board of Ambagon, ClearNote Health (formerly Bluestar), Circle, GLAdiator Biosciences, HAP10, Interdict Bio, Earli, ORIC Pharmaceuticals, Phoenix Molecular Designs, Trial Library and 280Bio (Yingli); is a consultant for Next RNA, Novartis and ProLynx; and holds patents on the use of PARP inhibitors, jointly with AstraZeneca from which he has benefited financially (and may do so in the future). N.M. is a cofounder of Genedit, Microbial Medical and Opus Biosciences. The other authors declare no competing interests.
